CeriBell (NASDAQ:CBLL) VP Sells $16,205.60 in Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 862 shares of CeriBell stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $18.80, for a total transaction of $16,205.60. Following the transaction, the vice president directly owned 37,751 shares of the company’s stock, valued at approximately $709,718.80. This trade represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Thursday, May 21st, David Foehr sold 987 shares of CeriBell stock. The shares were sold at an average price of $18.00, for a total transaction of $17,766.00.
• On Tuesday, March 3rd, David Foehr sold 4,560 shares of CeriBell stock. The stock was sold at an average price of $17.80, for a total transaction of $81,168.00.

CeriBell Stock Performance

CBLL traded up $0.03 on Tuesday, reaching $18.80. The company had a trading volume of 187,155 shares, compared to its average volume of 322,889. The stock has a market cap of $713.27 million, a P/E ratio of -11.53 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $24.33. The company’s fifty day moving average is $19.08 and its 200 day moving average is $19.19.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The firm had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. As a group, analysts predict that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CBLL. Strs Ohio bought a new stake in shares of CeriBell during the 1st quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CeriBell during the 3rd quarter worth $33,000. CWM LLC increased its holdings in CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after purchasing an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts recently commented on CBLL shares. BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. Canaccord Genuity Group cut their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Finally, Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.